CN Patent

CN101355930A — 用于纤维肌痛综合征长期治疗的米那普仑

Assigned to Cypress Bioscience Inc · Expires 2009-01-28 · 17y expired

What this patent protects

本发明涉及给纤维肌痛综合征患者使用双重再摄取抑制剂来对纤维肌痛综合征(FMS)提供长期治疗的方法。本发明尤其涉及给纤维肌痛综合征患者使用一种去甲肾上腺素－血清素再摄取抑制剂(NSRI)来长期治疗纤维肌痛综合征的方法。

USPTO Abstract

本发明涉及给纤维肌痛综合征患者使用双重再摄取抑制剂来对纤维肌痛综合征(FMS)提供长期治疗的方法。本发明尤其涉及给纤维肌痛综合征患者使用一种去甲肾上腺素－血清素再摄取抑制剂(NSRI)来长期治疗纤维肌痛综合征的方法。

Drugs covered by this patent

milnacipran-hydrochloride (MILNACIPRAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN101355930A
Jurisdiction: CN
Classification: —
Expires: 2009-01-28
Drug substance claim: No
Drug product claim: No
Assignee: Cypress Bioscience Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.